GlassScriptPhysician profile
Alison Armour
NPI 1215390182
$4,253.55
in general payments reported to CMS, 2019-2025
34 companies · $950 in 2025
The $950 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $414 · 2023: $1,199 · 2024: $1,204 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287 · Education: $65.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.90 |
| Education | $65.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.81 | 2021-2025 | |
| Tg Therapeutics, INC. | $533.48 | 2023-2025 | |
| Emd Serono, INC. | $481.09 | 2021-2025 | Mavenclad |
| Biogen, INC. | $354.97 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $268.28 | 2021-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $211.98 | 2021-2024 | Xcopri |
| Eisai INC. | $206.10 | 2023-2025 | |
| Genzyme Corporation | $180.93 | 2021-2025 | |
| Ucb, INC. | $162.41 | 2021-2024 | Fintepla |
| Pfizer INC. | $139.92 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $130.56 | 2022-2024 | Austedo Xr, Ajovy |
| Neurelis, INC. | $92.14 | 2021-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $82.93 | 2021-2024 | |
| Genentech USA, INC. | $76.48 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $52.57 | 2022-2023 | Hetlioz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $42.66 | 2021-2024 | Ultomiris |
| Lundbeck LLC | $42.62 | 2023-2024 | Vyepti |
| Tanabe Pharma America, INC. | $36.15 | 2023 | |
| Nevro Corp. | $33.38 | 2023 | Senza |
| Averitas Pharma INC. | $28.79 | 2024 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $27.59 | 2021 | |
| Amgen INC. | $25.34 | 2021 | |
| Tms Neurohealth Centers INC. | $25.00 | 2025 | Tms Neurohealth Centers INC. |
| Csl Behring | $23.06 | 2025 | Hizentra |
| Lilly USA, LLC | $22.23 | 2022 | |
| Acadia Pharmaceuticals INC | $19.56 | 2024 | Daybue |
| Amneal Pharmaceuticals LLC | $19.44 | 2021 | |
| Livanova USA, INC. | $18.23 | 2021 | |
| Celgene Corporation | $18.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.06 | 2023 | |
| Argenx US, INC. | $17.02 | 2025 | Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $16.27 | 2021 | |
| Medtronic, INC. | $14.75 | 2023 | Percept PC Brainsense |
| Tonix Medicines, INC. | $13.75 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Armour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.